公开(公告)号：US20240360239A1

公开(公告)日：2024-10-31

申请号：US18644984

申请日：2024-04-24

Applicant: Kling Biotherapeutics B.V.

Inventor： Hergen SPITS ,  Paula Maria Wilhelmina VAN HELDEN ,  Remko SCHOTTE ,  Wouter POS ,  Christien FATMAWATI ,  Danïel Michiel GO ,  Koen WAGNER ,  Julien Christian VILLAUDY

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  G01N33/574

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C07K14/70596 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  G01N2333/70596

Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.

公开(公告)号：US12122814B2

公开(公告)日：2024-10-22

申请号：US18501584

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US20240344102A1

公开(公告)日：2024-10-17

申请号：US18431564

申请日：2024-02-02

Applicant: Merus N.V.

Inventor： Cornelis Adriaan DE KRUIF ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC: C12P21/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  A61K39/00

CPC classification number: C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US20240342299A1

公开(公告)日：2024-10-17

申请号：US18670314

申请日：2024-05-21

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Amy Han

IPC: A61K47/68 ,  A61K31/58 ,  A61K31/685 ,  A61K31/7048 ,  A61K47/54 ,  C07J71/00 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/6803 ,  A61K31/58 ,  A61K31/685 ,  A61K31/7048 ,  A61K47/542 ,  A61K47/545 ,  A61K47/549 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6889 ,  C07J71/0031 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/41

Abstract: Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

公开(公告)号：US12116392B2

公开(公告)日：2024-10-15

申请号：US18501884

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US20240336702A1

公开(公告)日：2024-10-10

申请号：US18743295

申请日：2024-06-14

Applicant: AB STUDIO INC.

Inventor： Yue Liu ,  Wenyan Cai ,  Jiadong Shi

IPC: C07K16/46 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2896 ,  A61K2039/505

Abstract: This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.

公开(公告)号：US20240336699A1

公开(公告)日：2024-10-10

申请号：US18750233

申请日：2024-06-21

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Sonny Oon ANG ,  Enli LIU ,  Elizabeth SHPALL ,  Katy REZVANI

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P37/06 ,  C07K14/54 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N15/52 ,  C12N15/86

CPC classification number: C07K16/2896 ,  A61K35/17 ,  A61P37/06 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2863 ,  C12N15/52 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

公开(公告)号：US12110341B2

公开(公告)日：2024-10-08

申请号：US18640824

申请日：2024-04-19

Applicant: Genentech, Inc.

Inventor： Reed J. Harris ,  Paul A. Motchnik

IPC: C07K16/32 ,  A61K39/00 ,  C07K1/18 ,  C07K16/06 ,  C07K16/28 ,  G01N27/447 ,  G01N30/02

CPC classification number: C07K16/32 ,  C07K1/18 ,  C07K16/065 ,  C07K16/2863 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/76 ,  G01N27/447 ,  G01N30/02 ,  G01N2030/027

Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.

公开(公告)号：US12110339B2

公开(公告)日：2024-10-08

申请号：US17103807

申请日：2020-11-24

Applicant: ALPINE IMMUNE SCIENCES, INC.

Inventor： Ryan Swanson ,  Michael Kornacker

IPC: C07K14/705 ,  A61K39/00 ,  A61P37/06 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/2896 ,  C07K14/70532 ,  C07K16/461 ,  C07K2317/40 ,  C07K2319/01

Abstract: Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

公开(公告)号：US12110332B2

公开(公告)日：2024-10-08

申请号：US16765008

申请日：2017-11-20

Applicant: Taizhou Mabtech Pharmaceutical Co., Ltd.

Inventor： Yajun Guo

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/705

CPC classification number: C07K16/2827 ,  A61P35/00 ,  A61P37/02 ,  C07K14/70503 ,  C07K16/2896 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2319/70

Abstract: A bifunctional fusion protein targeting CD47 and PD-L1, which belongs to the field of biomedicine and solves the problems that anti-PD-1/PD-L1 treatment has poor effect on low immunogenic tumors and anti-CD47 treatment has poor targeting properties. The fusion protein consists of a CD47-binding moiety and a PD-L1-binding moiety linked by means of a disulfide bond, can block both the binding of CD47 to SIRPa and the binding of PD-L1 to PD-1, not only activating macrophage phagocytosis of tumor cells and promoting antigen presentation in innate immunity, but also promoting tumor-specific T cell activation in acquired immunity, and has lower hematological toxicity. The fusion protein has better anti-tumor efficacy and hematological safety than anti-PD-L1 or anti-CD47 therapy alone, and animals from which a tumor has disappeared after the treatment of the fusion protein produce immunity against re-inoculation of the same tumor cell.